Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies tumor samples from patients with ependymoma treated on the Children Oncology Group ACNS0121 trial.
| Condition | Intervention |
|---|---|
|
Brain and Central Nervous System Tumors |
Genetic: DNA analysis Genetic: cytogenetic analysis Genetic: fluorescence in situ hybridization Genetic: gene expression analysis Genetic: mutation analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis |
| Study Type: | Observational |
| Official Title: | Examination of the Multiple Genetic and Molecular Targets as Therapeutic Options for Patients With Ependymoma Treated by the Phase II Children's Oncology Group Study ACNS0121 |
- Association between OS and PFS with cell density, mitotic count, and tumor cell invasion [ Designated as safety issue: No ]
- Correlation between hTERT expression and telomere dysfunction and PFS and OS [ Designated as safety issue: No ]
- Role of 1q gain and 9p deletion and their association with PFS and OS [ Designated as safety issue: No ]
- Frequency and clinicopathological associations of mutations in genes involved in Notch pathway signaling [ Designated as safety issue: No ]
| Estimated Enrollment: | 80 |
| Study Start Date: | March 2012 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To examine the prognostic role of histopathological variables, in particular cellular density, mitotic count, and tumor cell invasion in intracranial pediatric ependymomas.
- To study whether hTERT expression and telomere dysfunction correlate with progression-free survival (PFS) and overall survival (OS) in pediatric intracranial ependymoma.
- To perform a genome-wide copy number screen and validation of copy number abnormalities (CNAs) on formalin-fixed paraffin-embedded (FFPE) ependymomas using Affymetrix Molecular Inversion Probe (MIP) arrays and interphase fluorescence in situ hybridization (iFISH).
- To evaluate associations between infiltration of immune markers and PFS as well as OS in pediatric ependymoma.
- To examine the role of 1q gain and 9p deletion in pediatric ependymomas by exploring their association with PFS and OS in a multivariable model.
- To establish the frequency and clinicopathological associations of mutations in genes involved in Notch pathway signaling.
OUTLINE: Archived tumor tissue samples are analyzed for cellular density, mitotic count, tumor cell invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by IHC, Affymetrix Molecular Inversion Probe (MIP) arrays, and fluorescence in situ hybridization (FISH). Results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location (infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.
Eligibility| Ages Eligible for Study: | 1 Year to 21 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Diagnosed with ependymoma and treated on COG-ACNS0121
- Previously collected tumor samples banked at the Children Oncology Group BioPathology
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Peter C. Adamson, Children's Oncology Group - Group Chair Office |
| ClinicalTrials.gov Identifier: | NCT01407744 History of Changes |
| Other Study ID Numbers: | CDR0000706818, COG-ACNS11B1 |
| Study First Received: | July 30, 2011 |
| Last Updated: | April 3, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
childhood infratentorial ependymoma childhood supratentorial ependymoma newly diagnosed childhood ependymoma |
Additional relevant MeSH terms:
|
Ependymoma Nervous System Neoplasms Central Nervous System Neoplasms Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms by Site Nervous System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013